For: | Huang KY, Wang FY, Lv M, Ma XX, Tang XD, Lv L. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World J Gastroenterol 2023; 29(26): 4120-4135 [PMID: 37475846 DOI: 10.3748/wjg.v29.i26.4120] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i26/4120.htm |
Number | Citing Articles |
1 |
Sulaiman A Alshammari, Mohsen N Almutairi, Mohammad O Alomar, Ziyad M Alsherif, Faisal H Alsubaie, Abdulrahman I Almezaini. Overlap Between Gastroesophageal Reflux Disease and Irritable Bowel Syndrome and Its Impact on Quality of Life. Cureus 2023; doi: 10.7759/cureus.50840
|
2 |
Jerlin Stephy JohnBritto, Agostino Di Ciaula, Antonino Noto, Velia Cassano, Angela Sciacqua, Mohamad Khalil, Piero Portincasa, Leonilde Bonfrate. Gender-specific insights into the irritable bowel syndrome pathophysiology. Focus on gut dysbiosis and permeability. European Journal of Internal Medicine 2024; doi: 10.1016/j.ejim.2024.03.011
|
3 |
Omid Vakili, Peyman Adibi Sedeh, Morteza Pourfarzam. Metabolic biomarkers in irritable bowel syndrome diagnosis. Clinica Chimica Acta 2024; 560: 119753 doi: 10.1016/j.cca.2024.119753
|
4 |
Bernhard Uehleke, Martin Storr, Martin Hörning. Grapefruit Seed Extract Reduces Gastrointestinal
Symptoms. Zeitschrift für Phytotherapie 2024; 45(02): 54 doi: 10.1055/a-2194-2206
|
5 |
Jun Zhao, Xia Li, Jiayi Yang, Xin Hao, Junjian Tian, Xin Wang, Xuefei Wang, Ning Li, Zhigang Li. Prevalence of and factors associated with symptoms consistent with a diagnosis of irritable bowel syndrome among resident physicians in standardised training in China: a cross-sectional study. BMJ Open 2023; 13(12): e079874 doi: 10.1136/bmjopen-2023-079874
|
6 |
Alexey M. Osadchuk, Irina D. Loranskaya, Mikhail A. Osadchuk. Comorbid functional pathology in gastroenterology. Possibilities and prospects for drug treatment: A review. Consilium Medicum 2024; 25(12): 844 doi: 10.26442/20751753.2023.12.202529
|
7 |
Shilan Mozaffari, Shekoufeh Nikfar, Mohammad Abdollahi. Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new?. Expert Opinion on Drug Metabolism & Toxicology 2024; 20(5): 307 doi: 10.1080/17425255.2024.2348488
|
8 |
Wei-Hao Chai, Yan Ma, Jia-Jia Li, Fei Guo, Yi-Zhan Wu, Jiang-Wei Liu. Immune cell signatures and causal association with irritable bowel syndrome: A mendelian randomization study. World Journal of Clinical Cases 2024; 12(17): 3094-3104 doi: 10.12998/wjcc.v12.i17.3094
Abstract(19) |
Core Tip(19) |
Full Article(HTML)(89)
|
Full Article with Cover (PDF)-9912K(4)
|
Full Article (Word)-1350K(0)
|
Audio-684K(0)
|
Peer-Review Report-195K(5)
|
Answering Reviewers-104K(4)
|
Full Article (PDF)-9454K(5)
|
Full Article (XML)-117K(4)
|
Times Cited (0)
|
Total Visits (329)
|
Open
|